BioSpace News Archive

Dr. Howard Landesman recognized by the American College of Prosthodontists.

MOORESTOWN, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety, will release its fourth quarter and full year 2019 operating results on Thursday, February 27, 2020 after market close, on the investor relations section of TRHC’s website at ir.trhc.com . A conference call hosted by Chairman and CEO, Calvin H. Knowlton, Ph.D., President and Chief Marketing and Business Development Officer, O

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 13, 2020 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and year ended December 31, 2019.

FDA grants Type C meeting for SB206 to be held on April 1, 2020 Last subject completes last visit, Week 24 safety evaluation Additional 12-week efficacy and safety data provided MORRISVILLE, N.C., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today provided an update on several aspects of its Phase 3 B-SIMPLE program (B-SIMPLE1 and B-SIMPLE2). Novan has been granted a Type C meeting with the U.S. Food and Drug Administration (“FDA”) on Apri

Arch Biopartners Inc.,, announced it has closed the non-brokered, unsecured convertible note financing it disclosed in a press release on February 4th for net proceeds of CAD $500,000.

The American Heart Association’s Go Red for Women® movement invites you to wear red with heart-health advocates nationwide demanding better care, greater inclusion of women in research

The company is lowering its full fiscal year 2020 revenue and adjusted diluted earnings per share guidance to reflect the impact of the remediation effort and anticipated loss of sales of the Alaris infusion system.

Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced the appointment of Mr. Siu Chuen Cheng as a new independent non-executive director to the Board of Directors of the Company (the “Board”).

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, and its development and commercialization partner, Chiesi Farmaceutici S.p.A.

PentixaPharm announced today to have secured € 15 million in a series A financing round led by ELSA Eckert Life Science Accelerator.